Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) announced a proposed underwritten public offering of $400 million of common stock or, for some investors, pre-funded warrants, with a 30-day underwriter option for up to $60 million additional shares. The offering is subject to market and other conditions.

Dianthus intends to use net proceeds to advance clinical and preclinical development, commercial readiness activities, and for working capital and general corporate purposes. Joint book-running managers include Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair.

Positive

• Proposed capital raise of $400 million to fund development
• Net proceeds designated for clinical and preclinical development and commercial readiness
• Experienced syndicate of joint book-running managers engaged for the offering

Negative

• Equity offering of $400 million may dilute existing shareholders
• Offering completion is uncertain — subject to market and other conditions
• Underwriters hold a 30-day option for up to $60 million, potentially increasing dilution

News Market Reaction – DNTH

+9.71% 2.4x vol

26 alerts

+9.71% News Effect

+11.4% Peak Tracked

-3.5% Trough Tracked

+$342M Valuation Impact

$3.86B Market Cap

2.4x Rel. Volume

On the day this news was published, DNTH gained 9.71%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.4% during that session. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $342M to the company's valuation, bringing the market cap to $3.86B at that time. Trading volume was elevated at 2.4x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Proposed offering size: $400 million Underwriters’ option: $60 million Shelf capacity: $600,000,000 +5 more

8 metrics

Proposed offering size $400 million Underwritten public offering of common stock and pre-funded warrants

Underwriters’ option $60 million 30-day option to purchase additional common stock

Shelf capacity $600,000,000 Maximum aggregate amount registered on S-3 shelf

2025 net loss $162.3 million Net loss for year ended Dec 31, 2025 (Form 8-K)

Cash & investments $514.4 million Cash, cash equivalents and investments as of Dec 31, 2025

Market value non-affiliates $599.4 million Market value held by non-affiliates as of Jun 30, 2025

Share price $65.04 Latest price before offering announcement

Short interest 29.81% Short interest as a percent of float

Market Reality Check

Price: $77.86 Vol: Volume 1,075,186 is 1.53x...

high vol

$77.86 Last Close

Volume Volume 1,075,186 is 1.53x the 20-day average of 704,419, indicating elevated activity pre-offering. high

Technical Shares at $65.04 are trading above the 200-day MA of $33.94 and near the $65.50 52-week high.

Peers on Argus

DNTH was up 6.14% with mixed peer moves: ELVN up 2.65%, NTLA up 5.58%, ZYME down...

1 Up

DNTH was up 6.14% with mixed peer moves: ELVN up 2.65%, NTLA up 5.58%, ZYME down 4.03%, others near flat. Peer momentum data flags no coordinated sector move, suggesting a company-specific catalyst.

Previous Offering Reports

3 past events · Latest: Sep 11 (Negative)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Sep 11	Offering closing	Negative	-1.9%	Closed upsized <b>$288M</b> equity and warrant financing including full overallotment.
Sep 09	Offering pricing	Negative	+6.5%	Priced upsized <b>$251M</b> underwritten offering at <b>$33.00</b> per share.
Sep 08	Offering proposal	Negative	+11.9%	Proposed <b>$150M</b> underwritten public offering plus <b>$22.5M</b> option.

Pattern Detected

Past offerings often saw mixed to positive price reactions despite dilutive overhang, with two out of three events showing gains.

Recent Company History

Over the past year, Dianthus has executed several equity offerings. A $150 million proposed deal on Sep 8, 2025, a priced upsized $251 million offering on Sep 9, 2025, and a closed upsized $288 million offering on Sep 11, 2025 all used common stock and pre-funded warrants. Those raises funded clinical development and corporate needs. Today’s $400 million proposed underwritten offering follows the same pattern of balance sheet-focused capital raises.

Historical Comparison

+5.5% avg move · Prior three offering-related headlines saw an average move of about 5.52%, with markets often reacti...

offering

+5.5%

Average Historical Move offering

Prior three offering-related headlines saw an average move of about 5.52%, with markets often reacting constructively despite dilution overhang.

Capital raises have scaled from a proposed $150M deal in Sep 2025 to larger upsized offerings, and now to a proposed $400M underwritten transaction, all aimed at funding the clinical pipeline.

Regulatory & Risk Context

Active S-3 Shelf · $600,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-28

$600,000,000 registered capacity

An effective S-3 shelf from Jan 28, 2026 allows Dianthus to issue up to $600,000,000 of various securities over time, and the proposed underwritten offering draws on this capacity for primary capital raising.

Market Pulse Summary

The stock moved +9.7% in the session following this news. A strong positive reaction aligns with pas...

Analysis

The stock moved +9.7% in the session following this news. A strong positive reaction aligns with past offering headlines where shares sometimes advanced despite dilution, as seen around Sep 8–9, 2025. With the stock already near its $65.50 52‑week high and trading above the 200‑day MA, enthusiasm could reflect confidence in funding the pipeline. However, a large primary raise under a $600M shelf may later cap upside if demand moderates.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, prospectus supplement, +1 more

5 terms

underwritten public offering financial

"it has commenced an underwritten public offering of $400 million of shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"in lieu of common stock to certain investors that so choose, pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement relating to these securities was filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"only by means of a written prospectus, including a prospectus supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"forming a part of an effective registration statement."

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. Not financial advice.

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus.

Dianthus intends to use the net proceeds from this offering to advance the Company’s clinical and preclinical development activities, commercial readiness activities as well as for working capital and general corporate purposes.

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as Dianthus’ financial advisor.

A shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (“SEC”) and became effective on January 30, 2026. This offering will be made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding Dianthus’ expectations regarding the proposed offering, including the timing, size, structure and completion of the proposed offering on the anticipated terms, the anticipated use of the net proceeds from the offering, the grant to the underwriters of the option to purchase additional shares and the potential value and clinical benefit of the Company’s product candidates. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of claseprubart, DNTH212 or the Company’s other compounds may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

What is the size and structure of the Dianthus (DNTH) offering announced on March 9, 2026?

Dianthus announced a proposed $400 million underwritten public offering, with an option for $60 million more. According to the company, securities may be common stock or pre-funded warrants and the offering is subject to market and other conditions.

How does Dianthus (DNTH) plan to use proceeds from the $400 million offering?

Dianthus intends to use net proceeds to advance clinical and preclinical programs and commercial readiness. According to the company, remaining funds are for working capital and general corporate purposes.

Will the Dianthus (DNTH) offering cause shareholder dilution and by how much?

The offering involves issuing new common stock or pre-funded warrants, so dilution is possible for existing shareholders. According to the company, the exact dilution depends on final offering size, exercise of the $60 million option, and investor choices.

Who are the lead underwriters for the DNTH proposed public offering announced March 9, 2026?

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair are joint book-running managers. According to the company, LifeSci Capital is acting as its financial advisor for the offering.

Is the Dianthus (DNTH) offering guaranteed to close and where can investors get the prospectus?

The offering is not guaranteed and is subject to market and other conditions, so completion is uncertain. According to the company, a preliminary prospectus supplement and prospectus will be available from the listed underwriters when available.